Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Instil Bio Inc (TIL)

Instil Bio Inc (TIL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 73,517
  • Shares Outstanding, K 6,782
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,140 K
  • EBIT $ -81 M
  • EBITDA $ -77 M
  • 60-Month Beta 2.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -2.31
  • Number of Estimates 1
  • High Estimate -2.31
  • Low Estimate -2.31
  • Prior Year -1.82
  • Growth Rate Est. (year over year) -26.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.70 +1.31%
on 12/02/25
15.23 -28.82%
on 11/13/25
-4.15 (-27.69%)
since 11/12/25
3-Month
10.70 +1.31%
on 12/02/25
25.89 -58.13%
on 09/15/25
-13.26 (-55.02%)
since 09/12/25
52-Week
10.70 +1.31%
on 12/02/25
42.79 -74.67%
on 06/10/25
-10.59 (-49.42%)
since 12/12/24

Most Recent Stories

More News
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported...

TIL : 10.84 (-1.09%)
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

ORR of 35% in previously treated squamous NSCLC patients with responses across PD-L1 TPS scores Differentiated structure of ‘2510 potentially results in best-in-class monotherapy activity in 2L+...

TIL : 10.84 (-1.09%)
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (“‘2510”) anticipated before the end of 2025 Updated ‘2510 monotherapy data in squamous-NSCLC...

TIL : 10.84 (-1.09%)
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting...

TIL : 10.84 (-1.09%)
Investors Turn to Cancer Breakthroughs as Federal Funding Faces Deep Cuts

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – With cancer cases rising and treatment costs hitting new highs, the private sector is under growing pressure...

ONCY : 0.9931 (-0.53%)
MGNX : 1.4000 (-0.71%)
AGEN : 3.79 (-7.11%)
TIL : 10.84 (-1.09%)
ONC.TO : 1.42 (+2.16%)
CATX : 2.67 (-1.11%)
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

TIL : 10.84 (-1.09%)
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

TIL : 10.84 (-1.09%)
ALNY : 397.55 (-3.65%)
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

TIL : 10.84 (-1.09%)
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

TIL : 10.84 (-1.09%)
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

TIL : 10.84 (-1.09%)

Business Summary

Instil Bio Inc. is a clinical-stage biopharmaceutical company. It is focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer. Instil Bio Inc. is based in DALLAS.

See More

Key Turning Points

3rd Resistance Point 12.00
2nd Resistance Point 11.71
1st Resistance Point 11.28
Last Price 10.84
1st Support Level 10.55
2nd Support Level 10.26
3rd Support Level 9.83

See More

52-Week High 42.79
Fibonacci 61.8% 30.53
Fibonacci 50% 26.75
Fibonacci 38.2% 22.96
Last Price 10.84
52-Week Low 10.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar